CN115380031A - 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 - Google Patents

作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 Download PDF

Info

Publication number
CN115380031A
CN115380031A CN202180025093.1A CN202180025093A CN115380031A CN 115380031 A CN115380031 A CN 115380031A CN 202180025093 A CN202180025093 A CN 202180025093A CN 115380031 A CN115380031 A CN 115380031A
Authority
CN
China
Prior art keywords
degrees
compound
formula
following
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180025093.1A
Other languages
English (en)
Inventor
钱文远
杨纯道
代国强
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN115380031A publication Critical patent/CN115380031A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Abstract

提供了一种作为ATM抑制剂的喹啉并吡咯烷‑2‑酮类化合物(I)的晶型及其制备方法，及其在制备治疗与实体瘤相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202180025093.1A 2020-03-30 2021-03-30 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 Pending CN115380031A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010237923 2020-03-30
CN2020102379234 2020-03-30
PCT/CN2021/084062 WO2021197339A1 (zh) 2020-03-30 2021-03-30 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用

Publications (1)

Publication Number Publication Date
CN115380031A true CN115380031A (zh) 2022-11-22

Family

ID=77929314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025093.1A Pending CN115380031A (zh) 2020-03-30 2021-03-30 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用

Country Status (2)

Country Link
CN (1) CN115380031A (zh)
WO (1) WO2021197339A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
WO2017194632A1 (en) * 2016-05-11 2017-11-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN107889488A (zh) * 2015-04-02 2018-04-06 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
CN108348515A (zh) * 2015-11-05 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN108349971A (zh) * 2015-11-03 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN112771045A (zh) * 2018-09-30 2021-05-07 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
CN107889488A (zh) * 2015-04-02 2018-04-06 默克专利股份公司 咪唑酮基喹啉和其作为atm激酶抑制剂的用途
CN108349971A (zh) * 2015-11-03 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN108348515A (zh) * 2015-11-05 2018-07-31 阿斯利康(瑞典)有限公司 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
WO2017194632A1 (en) * 2016-05-11 2017-11-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN112771045A (zh) * 2018-09-30 2021-05-07 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用

Also Published As

Publication number Publication date
WO2021197339A1 (zh) 2021-10-07

Similar Documents

Publication Publication Date Title
JP6820836B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
JP5926793B2 (ja) ブロモドメイン阻害剤としてのテトラヒドロキノリン誘導体
JP5856673B2 (ja) ７−（３，５−ジメチル−４−イソオキサゾリル）−８−（メチルオキシ）−１Ｈ−イミダゾ［４，５−ｃ］キノリン誘導体
TW202110836A (zh) 固態形式
EA022341B1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CN105189456A (zh) Kras g12c的共价抑制剂
WO2008097930A1 (en) Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
MXPA02005884A (es) Heteroaril-diazabicicloalcanos novedosos.
JP6946290B2 (ja) Ｍｎｋ阻害剤としてのピロロピリミジン化合物
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN117295742A (zh) 化合物ⅰ的新形式及它们的应用
CN110357852B (zh) 苯并嘧啶类化合物、制备方法和用途
CN115380031A (zh) 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
EP2547650B1 (en) Agomelatine hydrobromide hydrate and preparation thereof
TWI816690B (zh) 化合物的鹽及其晶型
WO2020228729A1 (zh) 喹唑啉酮类化合物的晶型及其制备方法
WO2021263246A1 (en) Novel cell metabolism modulating compounds and uses thereof
WO2019206268A1 (zh) 一种c-MET抑制剂的晶型及其盐型和制备方法
WO2022017208A1 (zh) 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
CN106478598B (zh) 一种凡德他尼水合物晶体及其制备方法
CN109516991A (zh) 一种枸橼酸托法替尼晶型化合物及其制备方法
WO2022016420A1 (zh) 一种喹唑啉酮类化合物的晶型、其制备方法及应用
US20140275234A1 (en) Compositions and methods of using crystalline forms of wortmannin analogs
WO2018099451A1 (zh) 化合物的晶型
CN111848580B (zh) 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination